Treats idiopathic pulmonary fibrosis (IPF). ANDA 218472, held by Humanwell Puracap. Nintedanib Esylate, Nintedanib.
As of Nov 16, 2026, ANDA 218472 (Nintedanib Esylate, Nintedanib), held by Humanwell Puracap, was first approved by FDA on Jul 9, 2026, with 0 approved supplements and 0 published complete response letters.
Nintedanib capsules are a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF). Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype 1.1 Idiopathic Pulmonary Fibrosis Nintedanib capsules are indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Nintedanib capsules are indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 2026 | Original application | Approved | None posted |
| Nintedanib EsylateEQ 100MG BASE · capsule;oral | Nintedanib Esylate | Rx |
| Nintedanib EsylateEQ 150MG BASE · capsule;oral | Nintedanib Esylate | Rx |
| Nintedanib25MG · capsule | Nintedanib | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters